Bone News and Research

RSS

Minimally invasive surgical techniques as effective as traditional open surgery in treating rectal cancers

Laparoscopic surgery has been used in the treatment of intestinal disorders for close to 20 years, but its benefits have only recently begun to be extended to people with rectal cancer. In a prospective study of 103 patients who underwent straightforward or "hand-assisted" laparoscopic surgery for rectal cancer, a team of colon and rectal surgeons at NewYork-Presbyterian Hospital/Weill Cornell Medical Center has shown that the minimally invasive approach can be as effective as traditional open surgery in treating rectal cancers.

11 Nov 2009

Data on Alexion Pharmaceuticals' Soliris to be presented at the ASH meeting

Alexion Pharmaceuticals, Inc. today announced that researchers are scheduled to present data relating to Soliris® (eculizumab) as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH) during the 51st Annual Meeting of the American Society of Hematology (ASH), to be held December 5 – 8, 2009 at the Ernst N. Morial Convention Center in New Orleans.

11 Nov 2009

Common myths about sun exposure, sunscreen and vitamin D

When it comes to vitamin D, consumers are bombarded with mixed messages about the best source for this essential nutrient. While some may argue that small doses of intentional sun exposure are safe, dermatologists point out that the risk of developing skin cancer from ultraviolet (UV) radiation far outweighs the benefit of stimulating vitamin D production - particularly when enriched foods and supplements are safe and effective sources of this vitamin.

11 Nov 2009

Bristol-Myers Squibb and Alder Biopharmaceuticals collaborate in development of novel biologic for rheumatoid arthritis

Bristol-Myers Squibb Company and Alder Biopharmaceuticals, Inc., today announced a global agreement for the development and commercialization of ALD518, a novel biologic that has completed Phase IIa development for the treatment of rheumatoid arthritis.

10 Nov 2009

Mesenchymal stem cells may be the key to healing diabetic foot ulcers

Diabetic foot ulcers are the primary cause of hospital admissions for diabetics. Foot ulcers that heal improperly are at risk for infection, which can lead to amputation. According to the American Diabetes Association, one in four patients with diabetic foot ulcers will eventually require lower-limb amputation. Now science has found a way of mobilizing stem cells within the body to treat this health issue, which affects more than three million Americans annually.

10 Nov 2009

Lawsuit against California Department of Health Care Services

AIDS Healthcare Foundation (AHF) has filed a federal lawsuit against David Maxwell-Jolly, Director of the California Department of Health Care Services (DHCS) seeking an injunction to prevent implementation of a new state law singling out nonprofit safety net providers—including AHF—forcing drastic Medi-Cal (Medicaid) reimbursements cuts for drugs purchased by AHF clinics and other safety net providers while favoring giant national for-profit pharmacy chains including Rite Aid, CVS, Walgreens and others.

10 Nov 2009

New school meal program can cause more harm than good, says nutrition experts

In attempts to improve the nutritional quality of school meals, there have been several strides forward - including the removal of soft drinks and other less nutritious menu options. However, some schools and activist groups are calling for a new change that many health professionals agree could cause more harm than good when it comes to children's health: removing chocolate milk from the lunch line.

10 Nov 2009

Study suggests a new improved treatment option for children with Hurler's syndrome

Researchers have transplanted genetically modified hematopoietic stem cells into mice so that their developing red blood cells produce a critical lysosomal enzyme - preventing or reducing organ and central nervous system damage from the often-fatal genetic disorder Hurler's syndrome.

10 Nov 2009

EpiCept announces third quarter 2009 financial results

EpiCept Corporation today announced operating and financial results for the three and nine months ended September 30, 2009, and provided an update on Ceplene® and several of the Company’s key product candidates.

10 Nov 2009

Harvest Technologies completes patient enrollment in its non-reconstructable Critical Limb Ischemia trial

Harvest Technologies Corp. announced today that the company sponsored 48-patient IDE clinical trial conducted at seven sites in the U.S. and one site in India using the company's Bone Marrow Aspiration Concentrate (BMAC) System to treat patients with non-reconstructable Critical Limb Ischemia (CLI) has completed enrollment. Mark D. Iafrati, M.D. Chief of Vascular Surgery at Tufts Medical Center in Boston, directed the study.

10 Nov 2009

FDA accepts ChemGenex Pharmaceuticals' NDA for Omapro

ChemGenex Pharmaceuticals Limited announced today that the U.S. Food & Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) for Omapro™ (omacetaxine mepesuccinate) for the treatment of patients with chronic myeloid leukemia (CML) who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation.

10 Nov 2009

FDA grants marketing approval for Wright Medical Group's CONSERVE Plus Total Hip Resurfacing System

Wright Medical Group, Inc., a global orthopaedic medical device company, announced today that the United States Food and Drug Administration (FDA) has given approval to the Company to market its original CONSERVE® Plus Total Hip Resurfacing System. Now available in the United States, this innovative total surface arthroplasty system provides surgeons and their patients a bone-conserving alternative to traditional total hip replacement.

9 Nov 2009

Positive study data from Zosano Pharma's ZP-PTH transdermal patch for treating osteoporosis

Zosano Pharma, Inc., a privately held pharmaceutical company developing products using a novel transdermal delivery technology, announced publication in the current issue of the Journal of Clinical Endocrinology and Metabolism of results from a positive phase 2 study of its rapid-delivery transdermal patch (ZP-PTH) for the treatment of postmenopausal osteoporosis.

9 Nov 2009

Emisphere Technologies' key product developments and financial results for the third quarter of 2009

Emisphere Technologies, Inc. today announced financial and operational results for the third quarter and nine months ended September 30, 2009.

9 Nov 2009

GTx reports financial results for the third quarter of 2009

GTx, Inc. today reported financial results for the third quarter of 2009. The net loss for the third quarter and nine months ended September 30, 2009 was $12.8 million and $35.4 million, respectively, compared with a net loss of $11.9 million and $37.9 million for the same periods in 2008. At September 30, 2009 GTx had cash, cash equivalents and short-term investments of $55.5 million.

9 Nov 2009

BrainStorm Cell Therapeutics' approach for treating neurodegenerative diseases shown to be effective

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies and therapeutics, is pleased to announce that the company’s therapeutic approach for treating neurodegenerative diseases was shown to be superior to other current potential stem cell treatments.

9 Nov 2009

$Connection between depression and loss of bone mass leads to osteoporosis and fractures$

Connection between depression and loss of bone mass leads to osteoporosis and fractures

Research carried out among thousands of people has shown a clear connection between depression and a loss of bone mass, leading to osteoporosis and fractures.

9 Nov 2009

Genetix Pharmaceuticals develops a gene therapy product to treat ALD

Genetix Pharmaceuticals, a leader in gene therapy of somatic stem cells, announced today the company’s clinical program to treat Adrenoleukodystrophy (ALD). The company is developing a gene therapy product in collaboration with Professor Patrick Aubourg and Doctor Nathalie Cartier of the National Institute of Health and Medical Research (INSERM).

7 Nov 2009

Positive interim data from the multicenter randomized Phase II trial of palifosfamide presented

ZIOPHARM Oncology, Inc. presented today at the 15th Annual Connective Tissue Oncology Society (CTOS) Meeting, positive interim data from the multicenter randomized Phase II trial of palifosfamide (ZymafosTM, ZIO-201) treating patients with unresectable or metastatic soft tissue sarcoma.

6 Nov 2009

Gene therapy saves two children with adrenoleukodystrophy

The ELA association and Zinedine Zidane, its emblematic ambassador, are proud to announce a world premiere: the results regaring the gene therapy in adrenoleukodystrophy conducted in France have just been published in the prestigious journal Science. Two children have been treated and their diseases have been halted. The children are doing well, which is unexpected for a disease destroying the brain in a few months. This discovery opens up treatment perspectives for numerous widespread diseases.

6 Nov 2009

Bone News and Research

Minimally invasive surgical techniques as effective as traditional open surgery in treating rectal cancers

Data on Alexion Pharmaceuticals' Soliris to be presented at the ASH meeting

Common myths about sun exposure, sunscreen and vitamin D

Bristol-Myers Squibb and Alder Biopharmaceuticals collaborate in development of novel biologic for rheumatoid arthritis

Mesenchymal stem cells may be the key to healing diabetic foot ulcers

Lawsuit against California Department of Health Care Services

New school meal program can cause more harm than good, says nutrition experts

Study suggests a new improved treatment option for children with Hurler's syndrome

EpiCept announces third quarter 2009 financial results

Harvest Technologies completes patient enrollment in its non-reconstructable Critical Limb Ischemia trial

FDA accepts ChemGenex Pharmaceuticals' NDA for Omapro

FDA grants marketing approval for Wright Medical Group's CONSERVE Plus Total Hip Resurfacing System

Positive study data from Zosano Pharma's ZP-PTH transdermal patch for treating osteoporosis

Emisphere Technologies' key product developments and financial results for the third quarter of 2009

GTx reports financial results for the third quarter of 2009

BrainStorm Cell Therapeutics' approach for treating neurodegenerative diseases shown to be effective

Connection between depression and loss of bone mass leads to osteoporosis and fractures

Genetix Pharmaceuticals develops a gene therapy product to treat ALD

Positive interim data from the multicenter randomized Phase II trial of palifosfamide presented

Gene therapy saves two children with adrenoleukodystrophy

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News